ITGB3 GENE POLYMORPHISM AND ITS RELATION TO PLATELET PHASE OF HEMOSTASIS ACTIVITY IN PATIENTS WITH CORONARY ARTERY DISEASE COMBINED WITH TYPE 2 DIABETES (24-29)

Архив в PDF формате
Дата публикации статьи в журнале: 2019/12/09
Название журнала: Восточно Европейский Научный Журнал, Выпуск: 51, Том: 2, Страницы в выпуске: 24-29
Автор: Karpenko O.O.
, Bogomolets National Medical University ,
Автор: Netiazhenko V.Z.
, Bogomolets National Medical University ,
Автор: Plenova O.M.
, Bogomolets National Medical University ,
Анотация: One of the urgent problems of modern health care is the elucidation of the molecular-genetic basis of the development of cardiovascular diseases. One of the effective approach to studying the role of genetic mechanisms of pathogenesis is associated with the selection of genes that have the greatest contribution to the regulation of primary hemostasis, ensuring the adequacy of the platelet response. The GP IIb/IIIa receptor is the major platelet receptor whose molecular defects can lead to platelet hyperaggregation. The ITGB3 gene (GPIIIa) encodes a protein component of the platelet fibrinogen receptor, which provides the interaction of platelets with blood plasma fibrinogen, resulting in platelet aggregation and thrombus formation. The main goal of the study is to assess platelet aggregation activity in patients with various forms of coronary artery disease in combination with type 2 diabetes and different polymorphism of ITGB3 gene.
Ключевые слова: platelets   gene polymorphism   thrombus   diabetes   aggregation  
Данные для цитирования: Karpenko O.O. , Netiazhenko V.Z. , Plenova O.M. . ITGB3 GENE POLYMORPHISM AND ITS RELATION TO PLATELET PHASE OF HEMOSTASIS ACTIVITY IN PATIENTS WITH CORONARY ARTERY DISEASE COMBINED WITH TYPE 2 DIABETES (24-29). Восточно Европейский Научный Журнал. Медицинские науки. 2019/12/09; 51(2):24-29.

Список литературы: 1. Bonfitto, P. H., Naime, A. C. A., Lopes-Pires, M. E., Goulart, G., Mendes-Silverio, C. B., Bueno, P. I., ... & Marcondes, S. (2018). Platelet activity is negatively modulated by tumor necrosis factor alpha through reductions of cytosolic calcium levels and integrin alphaIIbbeta3 phosphorylation. Thrombosis Research, 172, 44-50. 2. Feng, D., Lindpaintner, K., Larson, M. G., Rao, V. S., O’Donnell, C. J., Lipinska, I., ... & Muller, J. E. (1999). Increased platelet aggregability associated with platelet GPIIIa Pl A2 polymorphism: the Framingham Offspring Study. Arteriosclerosis, Thrombosis, and Vascular Biology, 19(4), 1142-1147. 3. Foster, J. G., Wood, S. K., Pfeffer, M. A., DeMets, D. L., Garber, A., & Hennekens, C. H. (2018). ASPIRIN FOR PRIMARY PREVENTION IN PATIENTS WITH TYPE 2 DIABETES. Endocrine Practice, 24(10), 925-927. 4. Grinshtein, Y. I., Kosinova, A. A., Grinshtein, I. Y., Subbotina, T. N., & Savchenko, A. A. (2018). The Prognostic Value of Combinations of Genetic Polymorphisms in the ITGB3, ITGA2, and CYP2C19* 2 Genes in Predicting Cardiovascular Outcomes After Coronary Bypass Grafting. Genetic testing and molecular biomarkers, 22(4), 259-265. 5. Jastrzebska, M., Lisman, D., Szelepajlo, A., Oledzki, S., Chelstowski, K., Clark, J. S., & Siennicka, A. (2019). Evaluation of platelet reactivity during combined antiplatelet therapy in patients with stable coronary artery disease in relation to diabetes type 2 and the GPIIB/IIIA receptor gene polymorphism. JPP, (2), 01. 6. Jiang, H., Su, R., & Hong, Q. (2019). Correlation Analysis of Platelet Aggregation Rate Detected by Platelet Analyzer, Platelet Aggregometer and Thromboelastography. Zhongguo shi yan xue ye xue za zhi, 27(5), 1622-1626. 7. Kafian, S., Wallén, H., Samad, B. A., & Mobarrez, F. (2019). Microvesicles from patients with acute coronary syndrome enhance platelet aggregation. Scandinavian journal of clinical and laboratory investigation, 79(7), 507-512. 8. Miyashita, N., Onozawa, M., Hayasaka, K., Yamada, T., Migita, O., Hata, K., ... & Kahata, K. (2018). A novel heterozygous ITGB3 p. T720del inducing spontaneous activation of integrin αIIbβ3 in autosomal dominant macrothrombocytopenia with aggregation dysfunction. Annals of hematology, 97(4), 629-640. 9. Quinn, M. J., Plow, E. F., & Topol, E. J. (2002). Platelet glycoprotein IIb/IIIa inhibitors: recognition of a two-edged sword?. Circulation, 106(3), 379-385. 10. Quinn, M. J., Byzova, T. V., Qin, J., Topol, E. J., & Plow, E. F. (2003). Integrin αIIbβ3 and its antagonism. Arteriosclerosis, thrombosis, and vascular biology, 23(6), 945-952. 11. Quinn, M. J., & Topol, E. J. (2001). Common variations in platelet glycoproteins: pharmacogenomic implications. Pharmacogenomics, 2(4), 341-352. 12. Shabana, N. A., Ashiq, S., Ijaz, A., Khalid, F., ul Saadat, I., Khan, K., ... & Shahid, S. U. (2018). Genetic risk score (GRS) constructed from polymorphisms in the PON1, IL-6, ITGB3, and ALDH2 genes is associated with the risk of coronary artery disease in Pakistani subjects. Lipids in health and disease, 17(1), 224.